2-Chloro-5-methylbenzimidazole acts as a reagent for the design and synthesis of prostate cancer antigen-1 (PCVIP(LA)1/ALKBH3) inhibitors as anti-prostate cancer drug, synthesis of unsymmetrical 2,2’-bisbenzimidazole sulfide of pharmacological interest.